Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Feb. 13, 2026	Regarding the Scheduled Review in Japan of the Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells (AMCHEPRY)	Products
Feb. 02, 2026	Posted Conference on Q3 FY2025 Financial Results [Webcast]	Finances
Jan. 30, 2026	Presentation Material (Conference on Q3 FY2025 Financial Results)（PDF/741KB）	Finances
Jan. 30, 2026	Supplementary Financial Data (IFRS) for the Third Quarte of the Year Ending March 31, 2026（PDF/261KB）	Finances
Jan. 30, 2026	Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 [IFRS]（PDF/446KB）	Finances
Dec. 22, 2025	Sumitomo Pharma Selected as “Best Website” for the Third Consecutive Year in Both All Markets and Pharmaceuticals Sector Categories of Nikko Investor Relations’ FY2025 All-Listed-Companies Website Ranking	Others

May 13, 2026	FY2025 financial results announcement (scheduled to be disclosed at 1:00 p.m.), conference on financial results FY2025 for Analysts, Investors, and the Press
Feb. 17, 2026	R&D Meeting